YH003 + pembrolizumab + nab-paclitaxel

YH003 + pembrolizumab + nab-paclitaxel is a combination regimen investigated primarily in oncology clinical trials, notably in first-line treatment for unresectable/metastatic mucosal melanoma. The regimen consists of three agents: - **YH003**: A humanized agonistic anti-CD40 monoclonal antibody. It binds to and agonizes the CD40 receptor, leading to activation of antigen-presenting cells (APCs) such as dendritic cells and macrophages, thereby boosting antitumor T-cell and immune responses. - **Pembrolizumab**: A monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) on T cells, preventing interaction with its ligands PD-L1 and PD-L2, thereby enhancing T-cell-mediated antitumor immunity. - **Nab-paclitaxel**: A nanoparticle albumin-bound formulation of the cytotoxic agent paclitaxel, which stabilizes microtubules and thus disrupts cell division in rapidly proliferating cancer cells. The combination is designed to synergize: the CD40 agonist amplifies dendritic cell activation and function, pembrolizumab removes immune suppression by blocking PD-1, and nab-paclitaxel delivers cytotoxic therapy while also increasing tumor antigen presentation via immunomodulatory effects. The main indication in trials is **unresectable/metastatic mucosal melanoma**[1][3][5].

Other names

YH003 + pembrolizumab + nab-paclitaxel